???global.info.a_carregar???
Grant McFadden.
Identificação

Identificação pessoal

Nome completo
Grant McFadden

Nomes de citação

  • McFadden, Grant

Identificadores de autor

Ciência ID
6510-1BBB-82E1
ORCID iD
0000-0002-2556-3526

Endereços de correio eletrónico

  • grantmcf@asu.edu (Profissional)

Moradas

  • Arizona State University - The Biodesign Institute. PO Box 877501, 85287-7501, Arizona, Tempe, Estados Unidos (Profissional)

Websites

Idiomas

Idioma Conversação Leitura Escrita Compreensão Peer-review
Inglês Utilizador proficiente (C1) Utilizador proficiente (C1) Utilizador proficiente (C1) Utilizador proficiente (C1)
Formação
Grau Classificação
1975
Concluído
 Biochemistry (Doktori fokozat (PhD))
Especialização em Biochemistry
McGill University Department of Biochemistry, Canadá
1970
Concluído
 Honors Biochemistry (Bachelor)
Especialização em Honors Biochemistry
McGill University Department of Biochemistry, Canadá
Percurso profissional

Cargos e Funções

Categoria Profissional
Instituição de acolhimento 		Empregador
2016 - Atual Professor Arizona State University School of Life Sciences, Estados Unidos
2016 - Atual Director Arizona State University Biodesign Institute Center for Immunotherapy, Vaccines and Virotherapy, Estados Unidos
2006 - 2016 Professor University of Florida College of Medicine, Estados Unidos
1997 - 2016 Professor Western University Department of Microbiology and Immunology, Canadá
1991 - 1996 Director, Group on the Molecular Mechanisms of Growth Control University of Alberta, Canadá
1989 - 1996 Professor University of Alberta Department of Biochemistry, Canadá
1987 - 1988 Sabbatical Research Harvard University Department of Microbiology and Immunology, Estados Unidos
1984 - 1988 Associate Professor University of Alberta Department of Biochemistry, Canadá
1981 - 1984 Assistant Professor University of Alberta Department of Biochemistry, Canadá
1976 - 1980 Postdoctoral Research Western University Department of Microbiology and Immunology, Canadá
Projetos

Bolsa

Designação Financiadores
2020/05/01 - 2021/04/30 Development of an intranasal COVID-19 vaccine that exploits SARS-CoV-2 Virus-like Particles
Fast Grants
Investigador responsável
Fast Grants (https://fastgrants.org/)
Em curso
2020/05 - 2021/04 Development of an intranasal COVID-19 vaccine that exploits SARS-CoV-2 Virus-like Particles
Fast Grants
 Fast Grants (https://fastgrants.org/)
2009/03 - 2020/11 Studies in Poxvirus Host Range Genes and Tropism
R01AI080607
 National Institute of Allergy and Infectious Diseases
2017/09 - 2019/08 Oncolytic Virotherapy with Myxoma Virus against Multiple Myeloma (Development Research Award)
Mayo Clinic SPORE
2013/01 - 2018/12 Manipulation of inflammasomes and NF-kB signaling in human myeloid cells by Myxom
R01AI100987
 National Institute of Allergy and Infectious Diseases
2015/05 - 2018 First-of-its-kind study of oncolytic virotherapy for Small Cell Lung Cancer (SCLC)
5JK04
 James Esther King Biomedical Research Program
2010/03 - 2015/12 Myxoma Virus (MV) Oncolysis for treating human cancer
R01CA138541
 National Cancer Institute
2014/06 - 2015/05 Ex vivo purging strategy for treatment of multiple myeloma
R41CA179706
 National Cancer Institute
2003/09 - 2014/02 Southeast Regional Centers of Excellence for Biodefense & Emerging Infectious Di
U54AI057157
 National Institute of Allergy and Infectious Diseases
2011/01 - 2012/12 Virotherapy for pancreatic cancer with wildtype and armed Myxoma viruses
R21CA149869
 National Cancer Institute
1996/04 - 2009/03 Role of intracellular signaling in poxvirus tropism
758993f9cffa5a69af2ba6af9a6f2742
 Canadian Institutes of Health Research
2004/07 - 2007/06 The Terry Fox New Frontiers Program Project Grant in Canadian oncolytic virus consortium
b4df3a1937af5c8831def3cf09dd6ecf
 Terry Fox Foundation
2002/07 - 2007/06 Anti-immune proteins of Yaba monkey tumour virus
899480fb38425107942de791096722bd
 Canadian Cancer Society
2005/10 - 2007/03 Inhibition of transplant vasculopathy by chemokine modulation
08b4b6bffb18a52069e4858e4a6ad54d
 Canadian Institutes of Health Research
1997/04 - 2007/03 Anti-immune proteins of myxoma virus
dc460b4778de4264dca20491ff275a87
 Canadian Institutes of Health Research
2001/07 - 2006/08 CANADA RESEARCH CHAIRHOLDER/ TITULAIRE DE CHAIRE DE RECHERCHE DU CANADA
469c3a468bf0b4330f2689c82ef49b30
 Canadian Institutes of Health Research
2003/07 - 2004/09 Characterization of poxvirus encoded pyrin-like proteins and their role in regulating inflammation and apoptosis
e08dd5b57fca3146021c1cbf1b9bfa2f
 Canadian Institutes of Health Research
2001/05 - 2004/04 The identification and analysis of a potential novel immunomodulatory gene (M141R) from Myxoma virus
5cb98600a8067e58dd49309632f56178
 Canadian Institutes of Health Research
2000/04 - 2003/09 Role of PKR-independent signaling in the induction of the antiviral state
43124b14249efa98b173c90640f075be
 Canadian Institutes of Health Research
2002/10 - 2002/12 Strategic training program in vaccine development and delivery
63497102e91cbcac3095614b4a45d81a
 Canadian Institutes of Health Research
1996/07 - 2001/06 Studies on the immune evasion strategies of poxviruses
9973f5655ce31cea251e64aa1b22b985
 Canadian Institutes of Health Research
1986/07 - 1999/09 Studies on the replication and oxidative stress responses of poxviruses
bad275cff227e775f101d67b6ca7243a
 Canadian Institutes of Health Research

Projeto

Designação Financiadores
2020/06/01 - 2022/11/30 Testing of COVID-19 monoclonal antibodies against SARS CoV-2 (Sponsored Research Agreement)
Amgen
Investigador responsável
Arizona State University, Estados Unidos
 Amgen Inc San Francisco
Em curso

Outro

Designação Financiadores
2019/06 - 2022/06 OncoMyx Therapeutics
OncoMyx Therapeutics
Em curso
2020/05/01 - 2021/04/30 Development of an intranasal COVID-19 vaccine that exploits SARS-CoV-2 Virus-like Particles (Catalyst Award)
Skysong Innovations (Catalyst Award)
Investigador responsável
Arizona State University SkySong
Em curso
Produções

Publicações

Artigo em revista
  1. Anne Everts; Melissa Bergeman; Grant McFadden; Vera Kemp. "Simultaneous Tumor and Stroma Targeting by Oncolytic Viruses". Biomedicines (2020): https://www.mdpi.com/2227-9059/8/11/474.
    10.3390/biomedicines8110474
  2. Masmudur M. Rahman; Grant McFadden. "Myxoma Virus-Encoded Host Range Protein M029: A Multifunctional Antagonist Targeting Multiple Host Antiviral and Innate Immune Pathways". Vaccines (2020): https://www.mdpi.com/2076-393X/8/2/244.
    10.3390/vaccines8020244
  3. McFadden, Grant. "Oncolytic Virotherapy with Myxoma Virus". Journal of clinical medicine (2020): https://europepmc.org/articles/PMC7020043.
    10.3390/jcm9010171
  4. McFadden, Grant. "Mesenchymal stem cells as carriers for systemic delivery of oncolytic viruses". European journal of pharmacology (2020): https://doi.org/10.1016/j.ejphar.2020.172991.
    10.1016/j.ejphar.2020.172991
  5. McFadden, Grant. "Oncolytic Viruses and the Immune System: The Dynamic Duo". Molecular therapy. Methods & clinical development (2020): https://europepmc.org/articles/PMC7015832.
    10.1016/j.omtm.2020.01.001
  6. McFadden, Grant. "Synergistic Combination of Oncolytic Virotherapy and Immunotherapy for Glioma". Clinical cancer research : an official journal of the American Association for Cancer Research (2020): https://doi.org/10.1158/1078-0432.CCR-18-3626.
    10.1158/1078-0432.ccr-18-3626
  7. McFadden, Grant. "Passing the Torch". PLoS pathogens (2020): https://europepmc.org/articles/PMC6991946.
    10.1371/journal.ppat.1008306
  8. McFadden, Grant. "Ex Vivo Virotherapy with Myxoma Virus to Treat Cancer". Methods in molecular biology (Clifton, N.J.) (2020): https://doi.org/10.1007/978-1-4939-9794-7_6.
    10.1007/978-1-4939-9794-7_6
  9. McFadden, Grant. "Genome characterization of cetaceanpox virus from a managed Indo-Pacific bottlenose dolphin (Tursiops aduncus)". Virus research (2020): https://doi.org/10.1016/j.virusres.2020.197861.
    10.1016/j.virusres.2020.197861
  10. McFadden, Grant. "Deriving Immune Modulating Drugs from Viruses-A New Class of Biologics". Journal of clinical medicine (2020): https://doi.org/10.3390/jcm9040972.
    10.3390/jcm9040972
  11. McFadden, Grant. "Coinfections of Novel Polyomavirus, Anelloviruses and a Recombinant Strain of Myxoma Virus-MYXV-Tol Identified in Iberian Hares". Viruses (2020): https://doi.org/10.3390/v12030340.
    10.3390/v12030340
  12. Garg, R.R.; Jackson, C.B.; Rahman, M.M.; Khan, A.R.; Lewin, A.S.; McFadden, G.. "Myxoma virus M013 protein antagonizes NF-¿B and inflammasome pathways via distinct structural motifs". Journal of Biological Chemistry 294 21 (2019): 8480-8489. http://www.scopus.com/inward/record.url?eid=2-s2.0-85066442007&partnerID=MN8TOARS.
    10.1074/jbc.RA118.006040
  13. McFadden, Grant. "Modifying the Organ Matrix Pre-engraftment: A New Transplant Paradigm?". Trends in molecular medicine (2019): https://doi.org/10.1016/j.molmed.2019.04.002.
    10.1016/j.molmed.2019.04.002
  14. McFadden, Grant. "A Virus-Derived Immune Modulating Serpin Accelerates Wound Closure with Improved Collagen Remodeling". Journal of clinical medicine (2019): https://europepmc.org/articles/PMC6832452.
    10.3390/jcm8101626
  15. McFadden, Grant. "Quantifying Antibody Responses Induced by Antigen-Agnostic Immunotherapies". Molecular therapy. Methods & clinical development (2019): https://europepmc.org/articles/PMC6677899.
    10.1016/j.omtm.2019.06.010
  16. McFadden, Grant. "Myxoma virus M013 protein antagonizes NF-¿B and inflammasome pathways via distinct structural motifs". The Journal of biological chemistry (2019): https://doi.org/10.1074/jbc.RA118.006040.
    10.1074/jbc.ra118.006040
  17. McFadden, Grant. "Genetic Characterization of a Recombinant Myxoma Virus in the Iberian Hare (Lepus granatensis)". Viruses (2019): https://europepmc.org/articles/PMC6631704.
    10.3390/v11060530
  18. McFadden, Grant. "Quantifying Antigen-Specific T Cell Responses When Using Antigen-Agnostic Immunotherapies". Molecular therapy. Methods & clinical development (2019): https://europepmc.org/articles/PMC6369252.
    10.1016/j.omtm.2019.01.012
  19. McFadden, Grant. "A cautionary note on the selectivity of oncolytic poxviruses". Oncolytic virotherapy (2019): https://europepmc.org/articles/PMC6375109.
    10.2147/OV.S189832
  20. McFadden, Grant. "Parallel adaptation of rabbit populations to myxoma virus". Science (New York, N.Y.) (2019): https://europepmc.org/articles/PMC6433279.
    10.1126/science.aau7285
  21. McFadden, Grant. "Oncolytic virotherapy for small-cell lung cancer induces immune infiltration and prolongs survival". The Journal of clinical investigation (2019): https://europepmc.org/articles/PMC6546459.
    10.1172/JCI121323
  22. McFadden, Grant. "Poxvirus oncolytic virotherapy". Expert opinion on biological therapy (2019): https://doi.org/10.1080/14712598.2019.1600669.
    10.1080/14712598.2019.1600669
  23. McFadden, Grant. "Author Correction: The wide utility of rabbits as models of human diseases". Experimental & molecular medicine (2019): https://europepmc.org/articles/PMC6802666.
    10.1038/s12276-019-0252-0
  24. Wolfe, A.; Rahman, M.; McFadden, D.G.; Bartee, E.C.. "Refinement and successful implementation of a scoring system for Myxomatosis in a susceptible rabbit (Oryctolagus cuniculus) model". Comparative Medicine 68 4 (2018): 280-285. http://www.scopus.com/inward/record.url?eid=2-s2.0-85060810593&partnerID=MN8TOARS.
    10.30802/AALAS-CM-18-000024
  25. McFadden, Grant. "Virotherapy as Potential Adjunct Therapy for Graft-Vs-Host Disease". Current pathobiology reports (2018): https://europepmc.org/articles/PMC6290699.
    10.1007/s40139-018-0186-6
  26. McFadden, Grant. "Oncolytic Virus-Mediated RAS Targeting in Rhabdomyosarcoma". Molecular Therapy Oncolytics (2018): https://europepmc.org/articles/PMC6197336.
    10.1016/j.omto.2018.09.001
  27. McFadden, Grant. "The wide utility of rabbits as models of human diseases". Experimental & molecular medicine (2018): https://europepmc.org/articles/PMC5964082.
    10.1038/s12276-018-0094-1
  28. McFadden, Grant. "White paper on microbial anti-cancer therapy and prevention". Journal for immunotherapy of cancer (2018): https://europepmc.org/articles/PMC6091193.
    10.1186/s40425-018-0381-3
  29. McFadden, Grant. "Crystal Structure of Cleaved Serp-1, a Myxomavirus-Derived Immune Modulating Serpin: Structural Design of Serpin Reactive Center Loop Peptides with Improved Therapeutic Function". Biochemistry (2018): https://doi.org/10.1021/acs.biochem.7b01171.
    10.1021/acs.biochem.7b01171
  30. McFadden, Grant. "Serpins: Development for Therapeutic Applications". Methods in molecular biology (Clifton, N.J.) (2018): https://doi.org/10.1007/978-1-4939-8645-3_17.
    10.1007/978-1-4939-8645-3_17
  31. McFadden, Grant. "Identification of host DEAD-box RNA helicases that regulate cellular tropism of oncolytic Myxoma virus in human cancer cells". Scientific reports (2017): https://europepmc.org/articles/PMC5691082.
    10.1038/s41598-017-15941-1
  32. McFadden, Grant. "Ex Vivo Oncolytic Virotherapy with Myxoma Virus Arms Multiple Allogeneic Bone Marrow Transplant Leukocytes to Enhance Graft versus Tumor". Molecular therapy oncolytics (2017): https://europepmc.org/articles/PMC5363758.
    10.1016/j.omto.2016.12.002
  33. McFadden, Grant. "Myxoma Virus dsRNA Binding Protein M029  Inhibits the Type I IFN-Induced Antiviral State in a  Highly Species-Specific Fashion". Viruses (2017): https://europepmc.org/articles/PMC5332946.
    10.3390/v9020027
  34. Villa, N.Y.; Rahman, M.M.; McFadden, G.; Cogle, C.R.. "Therapeutics for graft-versus-host disease: From conventional therapies to novel virotherapeutic strategies". Viruses 8 3 (2016): http://www.scopus.com/inward/record.url?eid=2-s2.0-85007372767&partnerID=MN8TOARS.
    10.3390/V8030085
  35. McFadden, Grant. "Therapeutics for Graft-versus-Host Disease: From Conventional Therapies to Novel Virotherapeutic Strategies". Viruses (2016): https://europepmc.org/articles/PMC4810275.
    10.3390/v8030085
  36. McFadden, Grant. "Myxoma virus M156 is a specific inhibitor of rabbit PKR but contains a loss-of-function mutation in Australian virus isolates". Proceedings of the National Academy of Sciences of the United States of America (2016): https://europepmc.org/articles/PMC4833222.
    10.1073/pnas.1515613113
  37. McFadden, Grant. "Ex vivo virotherapy with myxoma virus does not impair hematopoietic stem and progenitor cells". Cytotherapy (2016): https://europepmc.org/articles/PMC4748395.
    10.1016/j.jcyt.2015.12.007
  38. McFadden, Grant. "Vaccinia virus dissemination requires p21-activated kinase 1". Archives of virology (2016): https://doi.org/10.1007/s00705-016-2996-3.
    10.1007/s00705-016-2996-3
  39. McFadden, Grant. "M011L-deficient oncolytic myxoma virus induces apoptosis in brain tumor-initiating cells and enhances survival in a novel immunocompetent mouse model of glioblastoma". Neuro-oncology (2016): https://europepmc.org/articles/PMC4933479.
    10.1093/neuonc/now006
  40. McFadden, Grant. "SAMD9 is an innate antiviral host factor with stress response properties that can be antagonized by poxviruses". Journal of virology (2015): https://europepmc.org/articles/PMC4300762.
    10.1128/JVI.02262-14
  41. McFadden, Grant. "Evidence for differential viral oncolytic efficacy in an in vitro model of epithelial ovarian cancer metastasis". Molecular Therapy Oncolytics (2015): https://europepmc.org/articles/PMC4782950.
    10.1038/mto.2015.13
  42. McFadden, Grant. "Myxoma virus suppresses proliferation of activated T lymphocytes yet permits oncolytic virus transfer to cancer cells". Blood (2015): https://europepmc.org/articles/PMC4463738.
    10.1182/blood-2014-07-587329
  43. McFadden, Grant. "The a2,3-sialyltransferase encoded by myxoma virus is a virulence factor that contributes to immunosuppression". PloS one (2015): https://europepmc.org/articles/PMC4338283.
    10.1371/journal.pone.0118806
  44. McFadden, Grant. "Prevention of EBV lymphoma development by oncolytic myxoma virus in a murine xenograft model of post-transplant lymphoproliferative disease". Biochemical and biophysical research communications (2015): https://doi.org/10.1016/j.bbrc.2015.03.146.
    10.1016/j.bbrc.2015.03.146
  45. McFadden, Grant. "Gene delivery of a viral anti-inflammatory protein to combat ocular inflammation". Human gene therapy (2015): https://europepmc.org/articles/PMC4303190.
    10.1089/hum.2014.089
  46. McFadden, Grant. "In vitro screen of a small molecule inhibitor drug library identifies multiple compounds that synergize with oncolytic myxoma virus against human brain tumor-initiating cells". Neuro-oncology (2015): https://europepmc.org/articles/PMC4490869.
    10.1093/neuonc/nou359
  47. McFadden, Grant. "ATPS-65AN ONCOLYTIC MYXOMA VIRUS CONSTRUCT (M011L KNOCK-OUT) INDUCES APOPTOSIS AND IS A POTENT PRO-APOPTOTIC THERAPY IN BOTH HUMAN AND IMMUNOCOMPETENT MURINE GLIOBLASTOMA CANCER STEM CELLS MODELS". Neuro-oncology (2015): https://europepmc.org/articles/PMC4638488.
    10.1093/neuonc/nov204.65
  48. McFadden, Grant. "Editorial overview: Oncolytic viruses--replicating virus therapeutics for the treatment of cancer". Current opinion in virology (2015): https://doi.org/10.1016/j.coviro.2015.07.005.
    10.1016/j.coviro.2015.07.005
  49. McFadden, Grant. "Introducing “Research Matters”". PLoS pathogens (2015): https://europepmc.org/articles/PMC4482019.
    10.1371/journal.ppat.1005014
  50. McFadden, Grant. "The Curious Road from Basic Pathogen Research to Clinical Translation". PLoS pathogens (2015): https://europepmc.org/articles/PMC4481541.
    10.1371/journal.ppat.1004997
  51. McFadden, Grant. "ET-46ONCOLYTIC VIRAL THERAPY FOR MALIGNANT GLIOMAS USING MYXOMA VIRUS DELETED FOR ANTI-APOPTOTIC M11L GENE". Neuro-oncology (2014): https://europepmc.org/articles/PMC4218142.
    10.1093/neuonc/nou255.44
  52. McFadden, Grant. "Myxoma virus expressing a fusion protein of interleukin-15 (IL15) and IL15 receptor alpha has enhanced antitumor activity". PloS one (2014): https://europepmc.org/articles/PMC4199602.
    10.1371/journal.pone.0109801
  53. McFadden, Grant. "Cellular factors promoting resistance to effective treatment of glioma with oncolytic myxoma virus". Cancer research (2014): https://europepmc.org/articles/PMC4281961.
    10.1158/0008-5472.CAN-14-0876
  54. McFadden, Grant. "Recombinant myxoma virus lacking all poxvirus ankyrin-repeat proteins stimulates multiple cellular anti-viral pathways and exhibits a severe decrease in virulence". Virology (2014): https://europepmc.org/articles/PMC4157118.
    10.1016/j.virol.2014.06.021
  55. McFadden, Grant. "Oncolytic Poxviruses". Annual review of virology (2014): https://europepmc.org/articles/PMC4380149.
    10.1146/annurev-virology-031413-085442
  56. McFadden, Grant. "TUMOUR BIOLOGY". Neuro-oncology (2014): https://europepmc.org/articles/PMC4046298.
    10.1093/neuonc/nou082.25
  57. Davids, J.A.; Dai, E.; Chen, H.; Bartee, M.Y.; Liu, L.; Fortunel, A.; Moyer, R.; Mcfadden, G.; Lucas, A.R.. "Viral anti-inflammatory proteins target diverging immune pathways with converging effects on arterial dilatation, plaque and apoptosis". European Journal of Inflammation 12 1 (2014): 131-145. http://www.scopus.com/inward/record.url?eid=2-s2.0-84899095549&partnerID=MN8TOARS.
    10.1177/1721727X1401200113
  58. Lucas, A.; Eaverly, M.; McFadden, G.; Bryant, M.. "Women in cardiology: The x factor and the heart of medicine". Journal of Clinical and Experimental Cardiology 5 2 (2014): http://www.scopus.com/inward/record.url?eid=2-s2.0-84900816850&partnerID=MN8TOARS.
    10.4172/2155-9880.1000e134
  59. Lucas, A.; Ambadapadi, S.; Zheng, D.; Chen, H.; Lakshmyya, K.; Progulske-Fox, A.; Krafft, A.; et al. "The virome: Viral ghost companion, virus wars". Journal of Clinical and Experimental Cardiology 5 8 (2014): http://www.scopus.com/inward/record.url?eid=2-s2.0-84907483274&partnerID=MN8TOARS.
    10.4172/2155-9880.1000e136
  60. Mandl, K.D.; Kohane, I.S.; McFadden, D.; Weber, G.M.; Natter, M.; Mandel, J.; Schneeweiss, S.; et al. "Scalable collaborative infrastructure for a learning healthcare system (SCILHS): Architecture". Journal of the American Medical Informatics Association 21 4 (2014): 615-620. http://www.scopus.com/inward/record.url?eid=2-s2.0-84902371324&partnerID=MN8TOARS.
    10.1136/amiajnl-2014-002727
  61. McFadden, Grant. "Suppression of collagen-induced arthritis with a serine proteinase inhibitor (serpin) derived from myxoma virus". Clinical immunology (Orlando, Fla.) (2014): https://doi.org/10.1016/j.clim.2014.05.003.
    10.1016/j.clim.2014.05.003
  62. McFadden, Grant. "Targeting gallbladder cancer: oncolytic virotherapy with myxoma virus is enhanced by rapamycin in vitro and further improved by hyaluronan in vivo". Molecular cancer (2014): https://europepmc.org/articles/PMC4021541.
    10.1186/1476-4598-13-82
  63. McFadden, Grant. "Are we there yet? The smallpox research agenda using variola virus". PLoS pathogens (2014): https://europepmc.org/articles/PMC4006926.
    10.1371/journal.ppat.1004108
  64. McFadden, Grant. "Viruses for tumor therapy". Cell host & microbe (2014): https://europepmc.org/articles/PMC3963258.
    10.1016/j.chom.2014.01.002
  65. McFadden, Grant. "Evolution of viral sensing RIG-I-like receptor genes in Leporidae genera Oryctolagus, Sylvilagus, and Lepus". Immunogenetics (2014): https://doi.org/10.1007/s00251-013-0740-7.
    10.1007/s00251-013-0740-7
  66. McFadden, Grant. "Poxviruses and the evolution of host range and virulence". Infection, Genetics and Evolution (2014): https://europepmc.org/articles/PMC3945082.
    10.1016/j.meegid.2013.10.014
  67. McFadden, Grant. "Histological evaluation of intratumoral myxoma virus treatment in an immunocompetent mouse model of melanoma". Oncolytic virotherapy (2013): https://europepmc.org/articles/PMC4389688.
    10.2147/OV.S37971
  68. McFadden, Grant. "Myxoma and vaccinia viruses bind differentially to human leukocytes". Journal of virology (2013): https://europepmc.org/articles/PMC3624393.
    10.1128/JVI.03488-12
  69. McFadden, Grant. "The tanapoxvirus 15L protein is a virus-encoded neuregulin that promotes viral replication in human endothelial cells". Journal of virology (2013): https://europepmc.org/articles/PMC3592142.
    10.1128/JVI.02112-12
  70. McFadden, Grant. "The serpin solution; targeting thrombotic and thrombolytic serine proteases in inflammation". Cardiovascular & hematological disorders drug targets (2013): https://doi.org/10.2174/1871529x11313020003.
    10.2174/1871529x11313020003
  71. McFadden, Grant. "Myxomavirus-derived serpin prolongs survival and reduces inflammation and hemorrhage in an unrelated lethal mouse viral infection". Antimicrobial agents and chemotherapy (2013): https://europepmc.org/articles/PMC3754305.
    10.1128/AAC.02594-12
  72. McFadden, Grant. "Myxoma virus protein M029 is a dual function immunomodulator that inhibits PKR and also conscripts RHA/DHX9 to promote expanded host tropism and viral replication". PLoS pathogens (2013): https://europepmc.org/articles/PMC3701710.
    10.1371/journal.ppat.1003465
  73. McFadden, Grant. "Myxomaviral Anti-Inflammatory Serpin Reduces Myeloid-Derived Suppressor Cells and Human Pancreatic Cancer Cell Growth in Mice". Journal of cancer science & therapy (2013): https://europepmc.org/articles/PMC4367486.
    10.4172/1948-5956.1000219
  74. McFadden, Grant. "Evolution and divergence of the mammalian SAMD9/SAMD9L gene family". BMC evolutionary biology (2013): https://europepmc.org/articles/PMC3685527.
    10.1186/1471-2148-13-121
  75. McFadden, Grant. "Myxoma virus infection promotes NK lysis of malignant gliomas in vitro and in vivo". PloS one (2013): https://europepmc.org/articles/PMC3677932.
    10.1371/journal.pone.0066825
  76. McFadden, Grant. "Oncolytic myxoma virus: the path to clinic". Vaccine (2013): https://europepmc.org/articles/PMC3755036.
    10.1016/j.vaccine.2013.05.056
  77. McFadden, Grant. "Resistance to oncolytic myxoma virus therapy in nf1(-/-)/trp53(-/-) syngeneic mouse glioma models is independent of anti-viral type-I interferon". PloS one (2013): https://europepmc.org/articles/PMC3675064.
    10.1371/journal.pone.0065801
  78. McFadden, Grant. "Neutrophils recruited to sites of infection protect from virus challenge by releasing neutrophil extracellular traps". Cell host & microbe (2013): https://doi.org/10.1016/j.chom.2013.01.005.
    10.1016/j.chom.2013.01.005
  79. McFadden, Grant. "Cytokine synergy: an underappreciated contributor to innate anti-viral immunity". Cytokine (2013): https://europepmc.org/articles/PMC3748162.
    10.1016/j.cyto.2013.04.036
  80. McFadden, Grant. "Treating brain tumor-initiating cells using a combination of myxoma virus and rapamycin". Neuro-oncology (2013): https://europepmc.org/articles/PMC3688014.
    10.1093/neuonc/not035
  81. Chen, H.; Davids, J.A.; Zheng, D.; Bryant, M.; Bot, I.; van Berckel, T.J.C.; Biessen, E.; et al. "The serpin solution; targeting thrombotic and thrombolytic serine proteases in inflammation". Cardiovascular and Hematological Disorders - Drug Targets 13 2 (2013): 99-110. http://www.scopus.com/inward/record.url?eid=2-s2.0-84888094951&partnerID=MN8TOARS.
    10.2174/1871529X11313020003
  82. McFadden, Grant. "Positive evolutionary selection on the RIG-I-like receptor genes in mammals". PloS one (2013): https://europepmc.org/articles/PMC3842351.
    10.1371/journal.pone.0081864
  83. McFadden, Grant. "Interleukin-15 (IL-15) and IL-15 receptor alpha fusion protein enhances antitumor activity of myxoma virus". Journal for immunotherapy of cancer (2013): https://europepmc.org/articles/PMC3990353.
    10.1186/2051-1426-1-S1-P137
  84. McFadden, Grant. "The poxvirus C7L host range factor superfamily". Current opinion in virology (2012): https://europepmc.org/articles/PMC3508084.
    10.1016/j.coviro.2012.09.012
  85. McFadden, Grant. "Oncolytic virotherapy for ovarian cancer". Oncolytic virotherapy (2012): https://europepmc.org/articles/PMC4428588.
    10.2147/OV.S31626
  86. McFadden, Grant. "Virotherapy using myxoma virus prevents lethal graft-versus-host disease following xeno-transplantation with primary human hematopoietic stem cells". PloS one (2012): https://europepmc.org/articles/PMC3419197.
    10.1371/journal.pone.0043298
  87. McFadden, Grant. "Innate immune response of human plasmacytoid dendritic cells to poxvirus infection is subverted by vaccinia E3 via its Z-DNA/RNA binding domain". PloS one (2012): https://europepmc.org/articles/PMC3351467.
    10.1371/journal.pone.0036823
  88. McFadden, Grant. "Bugs and drugs: oncolytic virotherapy in combination with chemotherapy". Current pharmaceutical biotechnology (2012): https://europepmc.org/articles/PMC4373447.
    10.2174/138920112800958850
  89. McFadden, Grant. "Selective purging of human multiple myeloma cells from autologous stem cell transplantation grafts using oncolytic myxoma virus". Biology of Blood and Marrow Transplantation (2012): https://europepmc.org/articles/PMC3406238.
    10.1016/j.bbmt.2012.04.004
  90. McFadden, Grant. "Myxoma virus M064 is a novel member of the poxvirus C7L superfamily of host range factors that controls the kinetics of myxomatosis in European rabbits". Journal of virology (2012): https://europepmc.org/articles/PMC3347334.
    10.1128/JVI.06933-11
  91. McFadden, Grant. "Acute myeloid leukemia targeting by myxoma virus in vivo depends on cell binding but not permissiveness to infection in vitro". Leukemia research (2012): https://europepmc.org/articles/PMC3312971.
    10.1016/j.leukres.2012.01.020
  92. McFadden, Grant. "Myxoma virus sensitizes cancer cells to gemcitabine and is an effective oncolytic virotherapeutic in models of disseminated pancreatic cancer". Molecular therapy : the journal of the American Society of Gene Therapy (2012): https://europepmc.org/articles/PMC3321583.
    10.1038/mt.2011.293
  93. McFadden, Grant. "Myxoma virus-mediated oncolysis of ascites-derived human ovarian cancer cells and spheroids is impacted by differential AKT activity". Gynecologic oncology (2012): https://europepmc.org/articles/PMC4373451.
    10.1016/j.ygyno.2012.01.048
  94. McFadden, Grant. "Oncolytic virotherapy for hematological malignancies". Advances in virology (2012): https://europepmc.org/articles/PMC3265224.
    10.1155/2012/186512
  95. McFadden, Grant. "Modulation of NF-¿B signalling by microbial pathogens". Nature reviews. Microbiology (2011): https://europepmc.org/articles/PMC3611960.
    10.1038/nrmicro2539
  96. McFadden, Grant. "Intraventricular injection of myxoma virus results in transient expression of viral protein in mouse brain ependymal and subventricular cells". The Journal of general virology (2011): http://vir.sgmjournals.org/cgi/content/full/92/1/195.
    10.1099/vir.0.026690-0
  97. McFadden, Grant. "PRECLINICAL EXPERIMENTAL THERAPEUTICS AND PHARMACOLOGY". Neuro-oncology (2011): https://europepmc.org/articles/PMC3222964.
    10.1093/neuonc/nor158
  98. McFadden, Grant. "Myxoma Virus Induces Type I Interferon Production in Murine Plasmacytoid Dendritic Cells via a TLR9/MyD88-, IRF5/IRF7-, and IFNAR-Dependent Pathway". Journal of virology (2011): https://europepmc.org/articles/PMC3209359.
    10.1128/JVI.00104-11
  99. McFadden, Grant. "Myxoma virus lacking the pyrin-like protein M013 is sensed in human myeloid cells by both NLRP3 and multiple Toll-like receptors, which independently activate the inflammasome and NF-¿B innate response pathways". Journal of virology (2011): https://europepmc.org/articles/PMC3209384.
    10.1128/JVI.00410-11
  100. McFadden, Grant. "STEM CELLS". Neuro-oncology (2011): https://europepmc.org/articles/PMC3222962.
    10.1093/neuonc/nor163
  101. McFadden, Grant. "Tumor necrosis factor inhibitors from poxviruses with an emphasis on tanapoxvirus-2L protein". Recent patents on DNA & gene sequences (2011): https://doi.org/10.2174/187221511796392033.
    10.2174/187221511796392033
  102. McFadden, Grant. "Building bridges between plant and animal viruses". Current opinion in virology (2011): https://doi.org/10.1016/j.coviro.2011.10.004.
    10.1016/j.coviro.2011.10.004
  103. McFadden, Grant. "Myxoma virus combined with rapamycin treatment enhances adoptive T cell therapy for murine melanoma brain tumors". Cancer immunology, immunotherapy : CII (2011): https://europepmc.org/articles/PMC4378695.
    10.1007/s00262-011-1045-z
  104. McFadden, Grant. "The current status and future directions of myxoma virus, a master in immune evasion". Veterinary research (2011): https://europepmc.org/articles/PMC3131250.
    10.1186/1297-9716-42-76
  105. McFadden, Grant. "Production of Myxoma virus gateway entry and expression libraries and validation of viral protein expression". Current protocols in microbiology (2011): https://europepmc.org/articles/PMC3104670.
    10.1002/9780471729259.mc14a02s21
  106. McFadden, Grant. "Oncolytic virotherapy for pancreatic cancer". Expert reviews in molecular medicine (2011): https://europepmc.org/articles/PMC3230120.
    10.1017/S1462399411001876
  107. McFadden, Grant. "Viral serpin therapeutics from concept to clinic". Methods in enzymology (2011): https://europepmc.org/articles/PMC3558843.
    10.1016/B978-0-12-386471-0.00015-8
  108. McFadden, Grant. "M062 is a host range factor essential for myxoma virus pathogenesis and functions as an antagonist of host SAMD9 in human cells". Journal of virology (2011): https://europepmc.org/articles/PMC3067850.
    10.1128/JVI.02243-10
  109. McFadden, Grant. "A randomized controlled, phase 2 trial of the viral serpin Serp-1 in patients with acute coronary syndromes undergoing percutaneous coronary intervention". Circulation. Cardiovascular interventions (2010): https://doi.org/10.1161/CIRCINTERVENTIONS.110.953885.
    10.1161/circinterventions.110.953885
  110. McFadden, Grant. "Myxoma virus: propagation, purification, quantification, and storage". Current protocols in microbiology (2010): https://europepmc.org/articles/PMC2901999.
    10.1002/9780471729259.mc14a01s17
  111. McFadden, Grant. "Inhibition of chemokine-glycosaminoglycan interactions in donor tissue reduces mouse allograft vasculopathy and transplant rejection". PloS one (2010): https://europepmc.org/articles/PMC2865544.
    10.1371/journal.pone.0010510
  112. McFadden, Grant. "Myxoma and vaccinia viruses exploit different mechanisms to enter and infect human cancer cells". Virology (2010): https://europepmc.org/articles/PMC2862966.
    10.1016/j.virol.2010.02.027
  113. McFadden, Grant. "The immunoregulatory properties of oncolytic myxoma virus and their implications in therapeutics". Microbes and infection (2010): https://europepmc.org/articles/PMC2998584.
    10.1016/j.micinf.2010.08.012
  114. McFadden, Grant. "Killing a killer: what next for smallpox?". PLoS pathogens (2010): https://europepmc.org/articles/PMC2813274.
    10.1371/journal.ppat.1000727
  115. McFadden, Grant. "On the road to systems biology of host-pathogen interactions". Future microbiology (2010): https://doi.org/10.2217/fmb.09.130.
    10.2217/fmb.09.130
  116. McFadden, Grant. "Oncolytic viral purging of leukemic hematopoietic stem and progenitor cells with Myxoma virus". Cytokine & growth factor reviews (2010): https://europepmc.org/articles/PMC2881168.
    10.1016/j.cytogfr.2010.02.010
  117. McFadden, Grant. "Adipose-derived stem cells as therapeutic delivery vehicles of an oncolytic virus for glioblastoma". Molecular therapy : the journal of the American Society of Gene Therapy (2010): https://europepmc.org/articles/PMC2839314.
    10.1038/mt.2009.265
  118. McFadden, Grant. "Pharmacological manipulation of the akt signaling pathway regulates myxoma virus replication and tropism in human cancer cells". Journal of virology (2010): https://europepmc.org/articles/PMC2838123.
    10.1128/JVI.02020-09
  119. McFadden, Grant. "Myxoma virus virotherapy for glioma in immunocompetent animal models: optimizing administration routes and synergy with rapamycin". Cancer research (2010): http://cancerres.aacrjournals.org/cgi/content/full/70/2/598.
    10.1158/0008-5472.can-09-1510
  120. Tardif, J.-C.; L'Allier, P.L.; Grégoire, J.; Ibrahim, R.; McFadden, G.; Kostuk, W.; Knudtson, M.; et al. "A randomized controlled, phase 2 trial of the viral serpin serp-1 in patients with acute coronary syndromes undergoing percutaneous coronary intervention". Circulation: Cardiovascular Interventions 3 6 (2010): 543-548. http://www.scopus.com/inward/record.url?eid=2-s2.0-79953287029&partnerID=MN8TOARS.
    10.1161/CIRCINTERVENTIONS.110.953885
  121. Lun, X.; Alain, T.; Zemp, F.J.; Zhou, H.; Rahman, M.M.; Hamilton, M.G.; McFadden, G.; et al. "Myxoma virus virotherapy for glioma in immunocompetent animal models: Optimizing administration routes and synergy with rapamycin". Cancer Research 70 2 (2010): 598-608. http://www.scopus.com/inward/record.url?eid=2-s2.0-76549086994&partnerID=MN8TOARS.
    10.1158/0008-5472.CAN-09-1510
  122. Kim, M.; Williamson, C.T.; Prudhomme, J.; Bebb, D.G.; Riabowol, K.; Lee, P.W.K.; Lees-Miller, S.P.; et al. "The viral tropism of two distinct oncolytic viruses, reovirus and myxoma virus, is modulated by cellular tumor suppressor gene status". Oncogene 29 27 (2010): 3990-3996. http://www.scopus.com/inward/record.url?eid=2-s2.0-77954541596&partnerID=MN8TOARS.
    10.1038/onc.2010.137
  123. McFadden, Grant. "10 M-T7: measuring chemokine-modulating activity". Methods in enzymology (2009): https://doi.org/10.1016/S0076-6879(09)05210-0.
    10.1016/s0076-6879(09)05210-0
  124. McFadden, Grant. "The serpin saga; development of a new class of virus derived anti-inflammatory protein immunotherapeutics". Advances in experimental medicine and biology (2009): https://doi.org/10.1007/978-1-4419-1601-3_11.
    10.1007/978-1-4419-1601-3_11
  125. McFadden, Grant. "The addition of tumor necrosis factor plus beta interferon induces a novel synergistic antiviral state against poxviruses in primary human fibroblasts". Journal of virology (2009): https://europepmc.org/articles/PMC2612348.
    10.1128/JVI.01376-08
  126. McFadden, Grant. "Viral TNF inhibitors as potential therapeutics". Advances in experimental medicine and biology (2009): https://doi.org/10.1007/978-1-4419-1601-3_5.
    10.1007/978-1-4419-1601-3_5
  127. McFadden, Grant. "Interplay between poxviruses and the cellular ubiquitin/ubiquitin-like pathways". FEBS letters (2009): https://doi.org/10.1016/j.febslet.2009.01.023.
    10.1016/j.febslet.2009.01.023
  128. McFadden, Grant. "Myxoma virus targets primary human leukemic stem and progenitor cells while sparing normal hematopoietic stem and progenitor cells". Leukemia (2009): https://europepmc.org/articles/PMC3277946.
    10.1038/leu.2009.219
  129. McFadden, Grant. "Analysis of vaccinia virus-host protein-protein interactions: validations of yeast two-hybrid screenings". Journal of proteome research (2009): https://europepmc.org/articles/PMC2738428.
    10.1021/pr900491n
  130. McFadden, Grant. "Co-regulation of NF-kappaB and inflammasome-mediated inflammatory responses by myxoma virus pyrin domain-containing protein M013". PLoS pathogens (2009): https://europepmc.org/articles/PMC2762494.
    10.1371/journal.ppat.1000635
  131. McFadden, Grant. "Cytokine determinants of viral tropism". Nature reviews. Immunology (2009): https://europepmc.org/articles/PMC4373421.
    10.1038/nri2623
  132. McFadden, Grant. "Abstracts from the 2009 Joint Meeting of the Society for Neuro-Oncology (SNO) and the American Association of Neurological Surgeons/Congress of Neurological Surgeons (AANS/CNS) Section on Tumors: October 22–24, 2009: New Orleans, LA". Neuro-oncology (2009): https://europepmc.org/articles/PMC2765346.
    10.1215/15228517-2009-034
  133. McFadden, Grant. "Human cancer cells have specifically lost the ability to induce the synergistic state caused by tumor necrosis factor plus interferon-beta". Cytokine (2009): https://europepmc.org/articles/PMC4376283.
    10.1016/j.cyto.2009.06.006
  134. McFadden, Grant. "Inhibition of macrophage activation by the myxoma virus M141 protein (vCD200)". Journal of virology (2009): https://europepmc.org/articles/PMC2738222.
    10.1128/JVI.01078-09
  135. McFadden, Grant. "Cowpox virus expresses a novel ankyrin repeat NF-kappaB inhibitor that controls inflammatory cell influx into virus-infected tissues and is critical for virus pathogenesis". Journal of virology (2009): https://europepmc.org/articles/PMC2738262.
    10.1128/JVI.00861-09
  136. McFadden, Grant. "“Pearls”: A New Type of Open-Access Educational Resource". PLoS pathogens (2009): https://europepmc.org/articles/PMC2695540.
    10.1371/journal.ppat.1000499
  137. McFadden, Grant. "Proteomic screening of variola virus reveals a unique NF-kappaB inhibitor that is highly conserved among pathogenic orthopoxviruses". Proceedings of the National Academy of Sciences of the United States of America (2009): https://europepmc.org/articles/PMC2683884.
    10.1073/pnas.0900452106
  138. McFadden, Grant. "Myxoma virus M130R is a novel virulence factor required for lethal myxomatosis in rabbits". Virus research (2009): https://doi.org/10.1016/j.virusres.2009.05.009.
    10.1016/j.virusres.2009.05.009
  139. McFadden, Grant. "Virology in the 21st century". Journal of virology (2009): https://europepmc.org/articles/PMC2681991.
    10.1128/JVI.00151-09
  140. McFadden, Grant. "Myxoma virus expressing interleukin-15 fails to cause lethal myxomatosis in European rabbits". Journal of virology (2009): https://europepmc.org/articles/PMC2681933.
    10.1128/JVI.00204-09
  141. McFadden, Grant. "Induction of alpha/beta interferon by myxoma virus is selectively abrogated when primary mouse embryo fibroblasts become immortalized". Journal of virology (2009): https://europepmc.org/articles/PMC2681981.
    10.1128/JVI.02587-08
  142. McFadden, Grant. "Interaction of human TNF and beta2-microglobulin with Tanapox virus-encoded TNF inhibitor, TPV-2L". Virology (2009): https://doi.org/10.1016/j.virol.2009.01.026.
    10.1016/j.virol.2009.01.026
  143. McFadden, Grant. "Myxoma virus selectively disrupts type I interferon signaling in primary human fibroblasts by blocking the activation of the Janus kinase Tyk2". Virology (2009): https://doi.org/10.1016/j.virol.2009.02.013.
    10.1016/j.virol.2009.02.013
  144. McFadden, Grant. "Poxvirus proteomics and virus-host protein interactions". Microbiology and molecular biology reviews : MMBR (2009): https://europepmc.org/articles/PMC2786582.
    10.1128/MMBR.00026-09
  145. McFadden, Grant. "The myxoma virus m-t5 ankyrin repeat host range protein is a novel adaptor that coordinately links the cellular signaling pathways mediated by Akt and Skp1 in virus-infected cells". Journal of virology (2009): https://europepmc.org/articles/PMC2786711.
    10.1128/JVI.00963-09
  146. McFadden, Grant. "NFkB inhibitors: strategies from poxviruses". Cell cycle (Georgetown, Tex.) (2009): https://doi.org/10.4161/cc.8.19.9683.
    10.4161/cc.8.19.9683
  147. McFadden, Grant. "Tumor necrosis factor and interferon: cytokines in harmony". Current opinion in microbiology (2008): https://europepmc.org/articles/PMC7108444.
    10.1016/j.mib.2008.05.015
  148. McFadden, Grant. "Construction and testing of a novel host-range defective myxoma virus vaccine with the M063 gene inactivated that is non-permissive for replication in rabbit cells". Veterinary research (2008): https://doi.org/10.1051/vetres:2008037.
    10.1051/vetres:2008037
  149. McFadden, Grant. "RIG-I mediates the co-induction of tumor necrosis factor and type I interferon elicited by myxoma virus in primary human macrophages". PLoS pathogens (2008): https://europepmc.org/articles/PMC2438611.
    10.1371/journal.ppat.1000099
  150. McFadden, Grant. "PLoS Pathogens at three years". PLoS pathogens (2008): https://europepmc.org/articles/PMC2533063.
    10.1371/journal.ppat.1000167
  151. McFadden, Grant. "When good vaccines go wild: Feral Orthopoxvirus in developing countries and beyond". Journal of infection in developing countries (2008): https://doi.org/10.3855/jidc.258.
    10.3855/jidc.258
  152. McFadden, Grant. "Myxoma virus oncolysis of primary and metastatic B16F10 mouse tumors in vivo". Molecular therapy : the journal of the American Society of Gene Therapy (2008): https://europepmc.org/articles/PMC4376281.
    10.1038/sj.mt.6300348
  153. McFadden, Grant. "Yaba monkey tumor virus encodes a functional inhibitor of interleukin-18". Journal of virology (2008): https://europepmc.org/articles/PMC2224402.
    10.1128/JVI.00688-07
  154. McFadden, Grant. "The role of cell signaling in poxvirus tropism: the case of the M-T5 host range protein of myxoma virus". Biochimica et biophysica acta (2008): https://doi.org/10.1016/j.bbapap.2007.08.001.
    10.1016/j.bbapap.2007.08.001
  155. McFadden, Grant. "Inclusion of the viral anti-apoptotic molecule M11L in DNA vaccine vectors enhances HIV Env-specific T cell-mediated immunity". Virology (2008): https://doi.org/10.1016/j.virol.2008.01.011.
    10.1016/j.virol.2008.01.011
  156. McFadden, Grant. "Myxoma virus is oncolytic for human pancreatic adenocarcinoma cells". Annals of surgical oncology (2008): http://www.annalssurgicaloncology.org/cgi/content/full/15/8/2329.
    10.1245/s10434-008-9924-z
  157. McFadden, Grant. "Oncolytic efficacy of recombinant vesicular stomatitis virus and myxoma virus in experimental models of rhabdoid tumors". Clinical cancer research : an official journal of the American Association for Cancer Research (2008): https://europepmc.org/articles/PMC2844789.
    10.1158/1078-0432.CCR-07-1330
  158. McFadden, Grant. "Heparin alters viral serpin, serp-1, anti-thrombolytic activity to anti-thrombotic activity". The open biochemistry journal (2008): https://europepmc.org/articles/PMC2570549.
    10.2174/1874091X00802010006
  159. McFadden, Grant. "Poxvirus host range genes". Advances in virus research (2008): https://doi.org/10.1016/S0065-3527(08)00003-1.
    10.1016/s0065-3527(08)00003-1
  160. McFadden, Grant. "Innate immunity, tumor microenvironment and oncolytic virus therapy: friends or foes?". Current opinion in molecular therapeutics (2008): http://europepmc.org/abstract/MED/18228179.
  161. McFadden, Grant. "Change in the editorial leadership of PLoS Pathogens". PLoS pathogens (2008): https://europepmc.org/articles/PMC2323282.
    10.1371/journal.ppat.0040015
  162. Stanford, M.M.; Breitbach, C.J.; Bell, J.C.; McFadden, G.. "Innate immunity, tumor microenvironment and oncolytic virus therapy: Friends or foes?". Current Opinion in Molecular Therapeutics 10 1 (2008): 32-37. http://www.scopus.com/inward/record.url?eid=2-s2.0-38649123395&partnerID=MN8TOARS.
  163. Moussatché, N.; Damaso, C.R.; McFadden, G.. "When good vaccines go wild: Feral Orthopoxvirus in developing countries and beyond.". Journal of infection in developing countries 2 3 (2008): 156-173. http://www.scopus.com/inward/record.url?eid=2-s2.0-67650700335&partnerID=MN8TOARS.
  164. McFadden, Grant. "Induction of indefinite cardiac allograft survival correlates with toll-like receptor 2 and 4 downregulation after serine protease inhibitor-1 (Serp-1) treatment". Transplantation (2007): https://doi.org/10.1097/01.tp.0000286099.50532.b0.
    10.1097/01.tp.0000286099.50532.b0
  165. McFadden, Grant. "Abstracts for the Twelfth Annual Meeting of the Society for Neuro-Oncology: November 15–18, 2007". Neuro-oncology (2007): https://europepmc.org/articles/PMC1994106.
    10.1215/15228517-2007-039
  166. McFadden, Grant. "Myxoma virus in the European rabbit: interactions between the virus and its susceptible host". Veterinary research (2007): https://doi.org/10.1051/vetres:2006054.
    10.1051/vetres:2006054
  167. McFadden, Grant. "Structure of M11L: A myxoma virus structural homolog of the apoptosis inhibitor, Bcl-2". Protein science : a publication of the Protein Society (2007): https://europepmc.org/articles/PMC2203349.
    10.1110/ps.062720107
  168. McFadden, Grant. "Myxoma virus M063R is a host range gene essential for virus replication in rabbit cells". Virology (2007): https://doi.org/10.1016/j.virol.2006.11.015.
    10.1016/j.virol.2006.11.015
  169. McFadden, Grant. "M-T5, the ankyrin repeat, host range protein of myxoma virus, activates Akt and can be functionally replaced by cellular PIKE-A". Journal of virology (2007): https://europepmc.org/articles/PMC1865929.
    10.1128/JVI.01310-06
  170. McFadden, Grant. "Oncolytic virotherapy synergism with signaling inhibitors: Rapamycin increases myxoma virus tropism for human tumor cells". Journal of virology (2007): https://europepmc.org/articles/PMC1797522.
    10.1128/JVI.01408-06
  171. McFadden, Grant. "M135R is a novel cell surface virulence factor of myxoma virus". Journal of virology (2007): https://europepmc.org/articles/PMC1797242.
    10.1128/JVI.01633-06
  172. McFadden, Grant. "Immunopathogenesis of poxvirus infections: forecasting the impending storm". Immunology and cell biology (2007): https://doi.org/10.1038/sj.icb.7100033.
    10.1038/sj.icb.7100033
  173. McFadden, Grant. "Myxoma virus expressing human interleukin-12 does not induce myxomatosis in European rabbits". Journal of virology (2007): https://europepmc.org/articles/PMC2168987.
    10.1128/JVI.01483-07
  174. McFadden, Grant. "Targeting human medulloblastoma: oncolytic virotherapy with myxoma virus is enhanced by rapamycin". Cancer research (2007): https://europepmc.org/articles/PMC4380180.
    10.1158/0008-5472.CAN-07-1214
  175. McFadden, Grant. "Strategies that modulate inflammasomes: insights from host-pathogen interactions". Seminars in immunopathology (2007): https://doi.org/10.1007/s00281-007-0080-5.
    10.1007/s00281-007-0080-5
  176. McFadden, Grant. "Myxoma virus and oncolytic virotherapy: a new biologic weapon in the war against cancer". Expert opinion on biological therapy (2007): https://doi.org/10.1517/14712598.7.9.1415.
    10.1517/14712598.7.9.1415
  177. McFadden, Grant. "Tropism of Tanapox virus infection in primary human cells". Virology (2007): https://doi.org/10.1016/j.virol.2007.06.019.
    10.1016/j.virol.2007.06.019
  178. McFadden, Grant. "BAFfled by poxviruses?". Cell host & microbe (2007): https://doi.org/10.1016/j.chom.2007.05.002.
    10.1016/j.chom.2007.05.002
  179. McFadden, Grant. "Comparative genetic analysis of genomic DNA sequences of two human isolates of Tanapox virus". Virus research (2007): https://doi.org/10.1016/j.virusres.2007.05.001.
    10.1016/j.virusres.2007.05.001
  180. McFadden, Grant. "Identification of host range mutants of myxoma virus with altered oncolytic potential in human glioma cells". Journal of neurovirology (2007): https://doi.org/10.1080/13550280701591526.
    10.1080/13550280701591526
  181. McFadden, Grant. "Poxvirus cancer therapy". Recent patents on anti-infective drug discovery (2006): https://doi.org/10.2174/157489106778777592.
    10.2174/157489106778777592
  182. McFadden, Grant. "Poxvirus tumor necrosis factor receptor (TNFR)-like T2 proteins contain a conserved preligand assembly domain that inhibits cellular TNFR1-induced cell death". Journal of virology (2006): https://europepmc.org/articles/PMC1563942.
    10.1128/JVI.02449-05
  183. McFadden, Grant. "Variation in ligand binding specificities of a novel class of poxvirus-encoded tumor necrosis factor-binding protein". The Journal of biological chemistry (2006): https://doi.org/10.1074/jbc.M604645200.
    10.1074/jbc.m604645200
  184. McFadden, Grant. "Optimization of codon usage of poxvirus genes allows for improved transient expression in mammalian cells". Virus genes (2006): https://europepmc.org/articles/PMC7089053.
    10.1007/s11262-005-0035-7
  185. McFadden, Grant. "Prevention of chronic renal allograft rejection by SERP-1 protein". Transplantation (2006): https://doi.org/10.1097/01.tp.0000203141.02725.8a.
    10.1097/01.tp.0000203141.02725.8a
  186. McFadden, Grant. "Infection of human cancer cells with myxoma virus requires Akt activation via interaction with a viral ankyrin-repeat host range factor". Proceedings of the National Academy of Sciences of the United States of America (2006): https://europepmc.org/articles/PMC1450224.
    10.1073/pnas.0509341103
  187. McFadden, Grant. "Anti-immunology: evasion of the host immune system by bacterial and viral pathogens". Cell (2006): https://doi.org/10.1016/j.cell.2006.01.034.
    10.1016/j.cell.2006.01.034
  188. McFadden, Grant. "Identification of myxomaviral serpin reactive site loop sequences that regulate innate immune responses". The Journal of biological chemistry (2006): https://doi.org/10.1074/jbc.M509454200.
    10.1074/jbc.m509454200
  189. McFadden, Grant. "Myxoma virus M11L blocks apoptosis through inhibition of conformational activation of Bax at the mitochondria". Journal of virology (2006): https://europepmc.org/articles/PMC1346952.
    10.1128/JVI.80.3.1140-1151.2006
  190. Dai, E.; Viswanathan, K.; Yun, M.S.; Li, X.; Li, Y.L.; Togonu-Bickersteth, B.; Richardson, J.; et al. "Identification of myxomaviral serpin reactive site loop sequences that regulate innate immune responses". Journal of Biological Chemistry 281 12 (2006): 8041-8050. http://www.scopus.com/inward/record.url?eid=2-s2.0-33646373439&partnerID=MN8TOARS.
    10.1074/jbc.M509454200
  191. Johnston, J.B.; Barrett, J.W.; Nazarian, S.H.; Goodwin, M.; Ricciuto, D.; Wang, G.; McFadden, G.. "A Poxvirus-Encoded Pyrin Domain Protein Interacts with ASC-1 to Inhibit Host Inflammatory and Apoptotic Responses to Infection (DOI:10.1016/j.immuni.2005.10.003)". Immunity 25 4 (2006): 687-687. http://www.scopus.com/inward/record.url?eid=2-s2.0-33749509058&partnerID=MN8TOARS.
    10.1016/j.immuni.2006.10.003
  192. McFadden, Grant. "Modulation of tumor necrosis factor by microbial pathogens". PLoS pathogens (2006): https://europepmc.org/articles/PMC1383482.
    10.1371/journal.ppat.0020004
  193. Rahman, M.M.; Barrett, J.W.; Brouckaert, P.; McFadden, G.. "Variation in ligand binding specificities of a novel class of poxvirus-encoded tumor necrosis factor-binding protein". Journal of Biological Chemistry 281 32 (2006): 22517-22526. http://www.scopus.com/inward/record.url?eid=2-s2.0-33747371959&partnerID=MN8TOARS.
    10.1074/jbc.M604645200
  194. Johnston, J.B.; Wang, G.; Barrett, J.W.; Nazarian, S.H.; Colwill, K.; Moran, M.; McFadden, G.. "Myxoma virus M-T5 protects infected cells from the stress of cell cycle arrest through its interaction with host cell cullin-1". Journal of Virology 79 16 (2005): 10750-10763. http://www.scopus.com/inward/record.url?eid=2-s2.0-23244452458&partnerID=MN8TOARS.
    10.1128/JVI.79.16.10750-10763.2005
  195. McFadden, Grant. "Myxoma virus M141R expresses a viral CD200 (vOX-2) that is responsible for down-regulation of macrophage and T-cell activation in vivo". Journal of virology (2005): https://europepmc.org/articles/PMC1091733.
    10.1128/JVI.79.10.6052-6067.2005
  196. McFadden, Grant. "Myxoma virus infection of primary human fibroblasts varies with cellular age and is regulated by host interferon responses". Virology (2005): https://doi.org/10.1016/j.virol.2004.11.030.
    10.1016/j.virol.2004.11.030
  197. McFadden, Grant. "Poxvirus tropism". Nature reviews. Microbiology (2005): https://europepmc.org/articles/PMC4382915.
    10.1038/nrmicro1099
  198. McFadden, Grant. "A poxvirus-encoded pyrin domain protein interacts with ASC-1 to inhibit host inflammatory and apoptotic responses to infection". Immunity (2005): https://doi.org/10.1016/j.immuni.2005.10.003.
    10.1016/j.immuni.2005.10.003
  199. McFadden, Grant. "Expression profiling of herpesvirus and vaccinia virus proteins using a high-throughput baculovirus screening system". Journal of proteome research (2005): https://doi.org/10.1021/pr050137u.
    10.1021/pr050137u
  200. McFadden, Grant. "Myxoma virus is a novel oncolytic virus with significant antitumor activity against experimental human gliomas". Cancer research (2005): https://europepmc.org/articles/PMC4373463.
    10.1158/0008-5472.CAN-05-1201
  201. McFadden, Grant. "Current Status for High Titre Poxvirus Stock Preparation in CEF Under Serum-Free Medium Conditions: Implication for Vaccine Development". Cytotechnology (2005): https://europepmc.org/articles/PMC3449719.
    10.1007/s10616-005-3795-y
  202. McFadden, Grant. "Gleevec casts a pox on poxviruses". Nature medicine (2005): https://doi.org/10.1038/nm0705-711.
    10.1038/nm0705-711
  203. McFadden, Grant. "Myxoma virus M128L is expressed as a cell surface CD47-like virulence factor that contributes to the downregulation of macrophage activation in vivo". Virology (2005): https://doi.org/10.1016/j.virol.2005.03.037.
    10.1016/j.virol.2005.03.037
  204. McFadden, Grant. "The 'supervirus'? Lessons from IL-4-expressing poxviruses". Trends in immunology (2005): https://doi.org/10.1016/j.it.2005.04.001.
    10.1016/j.it.2005.04.001
  205. Seet, B.T.; McCaughan, C.A.; Handel, T.M.; Mercer, A.; Brunetti, C.; McFadden, G.; Fleming, S.B.. "Erratum: Analysis of an orf virus chemokine-binding protein: Shifting ligand specificities among a family of poxvirus viroceptors (Proceedings of the National Academy of Sciences of the United States of America (December 9, 2003) 110, 25 (15137-15142))". Proceedings of the National Academy of Sciences of the United States of America 101 14 (2004): 5180-5180. http://www.scopus.com/inward/record.url?eid=2-s2.0-1842687043&partnerID=MN8TOARS.
  206. Seet, B.T.; McFadden, G.. "Interaction analysis of viral cytokine-binding proteins using surface plasmon resonance.". Methods in molecular biology (Clifton, N.J.) 269 (2004): 219-242. http://www.scopus.com/inward/record.url?eid=2-s2.0-4043156895&partnerID=MN8TOARS.
  207. McFadden, Grant. "Smallpox: an ancient disease enters the modern era of virogenomics". Proceedings of the National Academy of Sciences of the United States of America (2004): https://europepmc.org/articles/PMC524071.
    10.1073/pnas.0406207101
  208. McFadden, Grant. "Disruption of Erk-dependent type I interferon induction breaks the myxoma virus species barrier". Nature immunology (2004): https://doi.org/10.1038/ni1132.
    10.1038/ni1132
  209. McFadden, Grant. "Technical knockout: understanding poxvirus pathogenesis by selectively deleting viral immunomodulatory genes". Cellular microbiology (2004): https://doi.org/10.1111/j.1462-5822.2004.00423.x.
    10.1111/j.1462-5822.2004.00423.x
  210. McFadden, Grant. "Secreted immunomodulatory viral proteins as novel biotherapeutics". Journal of immunology (Baltimore, Md. : 1950) (2004): https://doi.org/10.4049/jimmunol.173.8.4765.
    10.4049/jimmunol.173.8.4765
  211. McFadden, Grant. "Myxoma virus M11L prevents apoptosis through constitutive interaction with Bak". Journal of virology (2004): https://europepmc.org/articles/PMC421673.
    10.1128/JVI.78.13.7097-7111.2004
  212. McFadden, Grant. "Interaction analysis of viral cytokine-binding proteins using surface plasmon resonance". Methods in molecular biology (Clifton, N.J.) (2004): https://doi.org/10.1385/1-59259-789-0:219.
    10.1385/1-59259-789-0:219
  213. McFadden, Grant. "Viral chemokine-binding proteins inhibit inflammatory responses and aortic allograft transplant vasculopathy in rat models". Transplantation (2004): https://doi.org/10.1097/01.tp.0000131173.52424.84.
    10.1097/01.tp.0000131173.52424.84
  214. Liu, L.; Dai, E.; Miller, L.; Seet, B.; Lalani, A.; Macauley, C.; Li, X.; et al. "Viral chemokine-binding proteins inhibit inflammatory responses and aortic allograft transplant vasculopathy in rat models". Transplantation 77 11 (2004): 1652-1660. http://www.scopus.com/inward/record.url?eid=2-s2.0-2942633274&partnerID=MN8TOARS.
    10.1097/01.TP.0000131173.52424.84
  215. McFadden, Grant. "Poxviruses and immune evasion". Annual review of immunology (2003): https://doi.org/10.1146/annurev.immunol.21.120601.141049.
    10.1146/annurev.immunol.21.120601.141049
  216. McFadden, Grant. "Complete genomic sequence and comparative analysis of the tumorigenic poxvirus Yaba monkey tumor virus". Journal of Virology (2003): https://europepmc.org/articles/PMC296094.
    10.1128/JVI.77.24.13335-13347.2003
  217. McFadden, Grant. "Analysis of an orf virus chemokine-binding protein: Shifting ligand specificities among a family of poxvirus viroceptors". Proceedings of the National Academy of Sciences of the United States of America (2003): https://europepmc.org/articles/PMC299921.
    10.1073/pnas.2336648100
  218. McFadden, Grant. "Poxvirus immunomodulatory strategies: current perspectives". Journal of virology (2003): https://europepmc.org/articles/PMC155018.
    10.1128/JVI.77.11.6093-6100.2003
  219. McFadden, Grant. "Chemokine-binding viral protein M-T7 prevents chronic rejection in rat renal allografts". Transplantation (2003): https://doi.org/10.1097/01.TP.0000061604.57432.E3.
    10.1097/01.tp.0000061604.57432.e3
  220. McFadden, Grant. "A secreted high-affinity inhibitor of human TNF from Tanapox virus". Proceedings of the National Academy of Sciences of the United States of America (2003): https://europepmc.org/articles/PMC153641.
    10.1073/pnas.0737244100
  221. McFadden, Grant. "Role of the serine-threonine kinase PAK-1 in myxoma virus replication". Journal of virology (2003): https://europepmc.org/articles/PMC154029.
    10.1128/JVI.77.10.5877-5888.2003
  222. Dai, E.; Guan, H.; Liu, L.; Little, S.; McFadden, G.; Vaziri, S.; Cao, H.; et al. "Serp-1, a viral anti-inflammatory serpin, regulates cellular serine proteinase and serpin responses to vascular injury". Journal of Biological Chemistry 278 20 (2003): 18563-18572. http://www.scopus.com/inward/record.url?eid=2-s2.0-0038381452&partnerID=MN8TOARS.
    10.1074/jbc.M209683200
  223. McFadden, Grant. "Serp-1, a viral anti-inflammatory serpin, regulates cellular serine proteinase and serpin responses to vascular injury". The Journal of biological chemistry (2003): https://doi.org/10.1074/jbc.M209683200.
    10.1074/jbc.m209683200
  224. McFadden, Grant. "The PHD/LAP-domain protein M153R of myxomavirus is a ubiquitin ligase that induces the rapid internalization and lysosomal destruction of CD4". Journal of virology (2003): https://europepmc.org/articles/PMC140772.
    10.1128/JVI.77.2.1427-1440.2003
  225. Bédard, E.L.R.; Kim, P.; Jiang, J.; Parry, N.; Liu, L.; Wang, H.; Garcia, B.; et al. "Chemokine-binding viral protein M-T7 prevents chronic rejection in rat renal allografts". Transplantation 76 1 (2003): 249-252. http://www.scopus.com/inward/record.url?eid=2-s2.0-0037962278&partnerID=MN8TOARS.
    10.1097/01.TP.0000061604.57432.E3
  226. McFadden, Grant. "Smallpox: anything to declare?". Nature reviews. Immunology (2002): https://doi.org/10.1038/nri845.
    10.1038/nri845
  227. McFadden, Grant. "Overexpression of alcohol dehydrogenase exacerbates ethanol-induced contractile defect in cardiac myocytes". American journal of physiology. Heart and circulatory physiology (2002): http://intl-ajpheart.physiology.org/cgi/content/full/282/4/H1216.
    10.1152/ajpheart.00780.2001
  228. McFadden, Grant. "Leporipoxvirus Cu-Zn superoxide dismutase homologs inhibit cellular superoxide dismutase, but are not essential for virus replication or virulence". Virology (2002): https://doi.org/10.1006/viro.2002.1383.
    10.1006/viro.2002.1383
  229. McFadden, Grant. "Immune responses to myxoma virus". Viral immunology (2002): https://doi.org/10.1089/08828240260066198.
    10.1089/08828240260066198
  230. McFadden, Grant. "Characterization of a pan-species reactive monoclonal antibody specific for a cell surface epitope which could serve as a marker for human monocytic and megakaryocytic differentiation". Hybridoma and hybridomics (2002): https://doi.org/10.1089/153685902321043972.
    10.1089/153685902321043972
  231. McFadden, Grant. "Characterization of a monoclonal antibody specific for a novel primate cell surface marker with distinct biochemical properties on human erythroleukemia and myeloid cell lines". Hybridoma and hybridomics (2002): https://doi.org/10.1089/153685902760213886.
    10.1089/153685902760213886
  232. McFadden, Grant. "The myxoma poxvirus protein, M11L, prevents apoptosis by direct interaction with the mitochondrial permeability transition pore". The Journal of experimental medicine (2002): https://europepmc.org/articles/PMC2194110.
    10.1084/jem.20011247
  233. McFadden, Grant. "Viral chemokine-binding proteins". Journal of leukocyte biology (2002): http://www.jleukbio.org/cgi/content/full/72/1/24.
  234. McFadden, Grant. "Poxviruses and apoptosis: a time to die". Current opinion in microbiology (2002): https://doi.org/10.1016/s1369-5274(02)00340-5.
    10.1016/s1369-5274(02)00340-5
  235. McFadden, Grant. "Molecular determinants for CC-chemokine recognition by a poxvirus CC-chemokine inhibitor". Proceedings of the National Academy of Sciences of the United States of America (2001): https://europepmc.org/articles/PMC55364.
    10.1073/pnas.171069398
  236. McFadden, Grant. "Identification of a gammaherpesvirus selective chemokine binding protein that inhibits chemokine action". Journal of virology (2000): https://europepmc.org/articles/PMC112190.
    10.1128/jvi.74.15.6741-6747.2000
  237. McFadden, Grant. "M11L: a novel mitochondria-localized protein of myxoma virus that blocks apoptosis of infected leukocytes". The Journal of experimental medicine (2000): https://europepmc.org/articles/PMC2213443.
    10.1084/jem.191.9.1487
  238. McFadden, Grant. "The viral anti-inflammatory chemokine-binding protein M-T7 reduces intimal hyperplasia after vascular injury". The Journal of clinical investigation (2000): https://europepmc.org/articles/PMC300852.
    10.1172/jci8934
  239. McFadden, Grant. "Mechanism of replication of phi x174 single-stranded DNA. IX. Requirement for the Escherichia coli dnaG protein". Journal of virology (1974): https://europepmc.org/articles/PMC355621.
Capítulo de livro
  1. Barrett, J.W.; McFadden, G.. "Tanapox virus". 1039-1046. 2016.
  2. Ambadapadi, S.; Chen, H.; Zheng, D.; Liu, L.; Dai, E.; Munuswamy-Ramanujam, G.; Morshed, S.; et al. "Serpins, viruses, and the virome: New directions in therapy". 293-329. 2015.
  3. McFadden, G.. "Leporipoviruses and Suipoxviruses". 225-230. 2008.
  4. Barrett, J.W.; McFadden, G.. "Yatapoxviruses". 461-465. 2008.
  5. Barrett, J.W.; McFadden, G.. "Origin and Evolution of Poxviruses". 431-446. 2008.
  6. Johnston, J.B.; McFadden, G.. "Immunomodulation by poxviruses: Insights into virus-host interactions by selectively deleting poxvirus genes". 163-195. 2005.
Livro
  1. Bartee, M.Y.; Dai, E.; Liu, L.; Munuswamy-Ramanujam, G.; Macaulay, C.; McIvor, D.; McFadden, G.; Lucas, A.R.. Chapter 10 M-T7. Measuring Chemokine-Modulating Activity. 2009.
    10.1016/S0076-6879(09)05210-0
  2. Werden, S.J.; Rahman, M.M.; McFadden, G.. Chapter 3 Poxvirus Host Range Genes. 2008.
    10.1016/S0065-3527(08)00003-1
Atividades

Arbitragem científica em revista

Nome da revista (ISSN) Editora
2017 - Atual Molecular Therapy — Oncolytics (2372-7705) Elsevier

Membro de associação

Nome da associação Tipo de participação
2011 - Atual American Society of Gene and Cell Therapy Member
1982 - Atual American Society for Virology Member
1982 - Atual American Society for Microbiology Member
2001 - 2017 Faculty of 1000 Member
1997 - 2016 International Cytokine Society Member
1995 - 2016 Who's Who in Science and Engineering Inductee
1995 - 2016 American Society for Leukocyte Biology Member
1989 - 2016 American Association for the Advancement of Science
Distinções

Prémio

2013 U Florida College of Medicine Basic Science Research Award
2012 U Florida Research Foundation (UFRF) Professorship Award (2012-14)
2001 Ontario Innovation Trust, Ontario Distinguished Researcher Award
1996 MRC Senior Scientist award (1996-2001)

Outra distinção

2017 International Union of Microbial Sciences, Singapore (IUMS 2017), Keynote Speaker
2015 American Society for Virology, Elected President (2015-16)
2014 Danny Thomas 2014 Lecturer, St. Jude Hospital, Memphis, TN USA
2011 Remi Amelunxen Symposium, U Kansas, Kansas City USA, Keynote Speaker
2009 Sidney E. Grossberg Lecture, Medical College of Wisconsin, WI
2009 Beijerinck Award Lecturer, Amsterdam, the Netherlands
2007 American Society of Microbiology, Fellow
2005 Howard Hughes Medical Institute International Scholarship (2005-08)
2005 Prix Galien Award (to VIRON, co-founded by G. McFadden & A. Lucas)
2004 Canadian Academy of Health Sciences, Fellow
2004 Royal Society of Canada, Fellow
2004 ASM Division E. Lecture Award, New Orleans
2004 Allan Granoff Lecturer Award, St. Jude’s Hospital
2002 Dean’s Award of Excellence, U. Western Ontario
2002 The Hellmuth Prize for Research Excellence
2001 Canada Research Chair in Molecular Virology (2001-06)
2001 Canada Research Chair (Tier I), U. Western Ontario (2001-06)
2001 Von Royen Lectureship, Dalhousie
2000 Marcel-Piché Lectureship, Montreal